Net sales (USD, millions)

Cost of products sold, excluding amortization of intangible assets (USD, millions)

Amortization of intangible assets (USD, millions)

Research and development (USD, millions)

Selling, general and administrative (USD, millions)

Total operating cost and expenses (USD, millions)

Operating earnings (USD, millions)

Interest expense (USD, millions)

Interest (income) (USD, millions)

Net foreign exchange (gain) loss (USD, millions)

Other (income) expense, net (USD, millions)

Earnings before taxes (USD, millions)

Taxes on earnings (USD, millions)

Net Earnings (USD, millions)

Basic Earnings Per Common Share (USD)

Diluted Earnings Per Common Share (USD)

11af0d6f5824b687228d8fff87f9e230a024d16fc569c4eee093072783d34f36

Net earnings (USD, millions)

Depreciation (USD, millions)

Share-based compensation (USD, millions)

Other, net (Operating Activities) (USD, millions)

Net Cash From Operating Activities (USD, millions)

Acquisitions of property and equipment (USD, millions)

Acquisitions of businesses and technologies, net of cash acquired (USD, millions)

Proceeds from business dispositions (USD, millions)

Sales (purchases) of other investment securities, net (USD, millions)

Other (Investing Activities) (USD, millions)

Net Cash From (Used in) Investing Activities (USD, millions)

Net borrowings (repayments) of short-term debt and other (USD, millions)

Proceeds from issuance of long-term debt (USD, millions)

Repayments of long-term debt (USD, millions)

Purchases of common shares (USD, millions)

Proceeds from stock options exercised (USD, millions)

Dividends paid (USD, millions)

Net Cash From (Used in) Financing Activities (USD, millions)

Effect of exchange rate changes on cash and cash equivalents (USD, millions)

Net Increase (Decrease) in Cash and Cash Equivalents (USD, millions)

Investing and financing losses, net (USD, millions)

Income taxes (USD, millions)

Proceeds from issuance of (repayments of) short-term debt, net and other (USD, millions)

Proceeds from issuance of long-term debt and debt with maturities over 3 months (USD, millions)

Repayments of long-term debt and debt with maturities over 3 months (USD, millions)

Trade receivables (USD, millions)

Inventories (USD, millions)

Cash and Cash Equivalents, Beginning of Year (USD, millions)

Cash and Cash Equivalents, End of Period (USD, millions)

Prepaid expenses and other assets (USD, millions)

Trade accounts payable and other liabilities (USD, millions)

81bcb1e603ef99f397666c7e8ee82d2ed0a9ad3ffe7ebb2f6ddd2983d107a1fa

Abbott Laboratories’ cash and cash equivalents dropped sharply in Q1 2024 as a result of several factors. The company paid significant dividends and made substantial capital expenditures during the quarter, which directly reduced its cash reserves. Although these outflows were partially offset by **$1.0 billion** generated from operating activities, the overall effect was a reduction in cash. Additionally, a broader decline in working capital, including an increase in the current portion of long-term debt, contributed to the drop.  **[0001628280-24-020011_abt-20240331.htm:21]** **[0001628280-24-020011_abt-20240331.htm:2]** 

Why did Cash and cash equivalents drop so sharply in Q1 2024?

**The surge in the current portion of long-term debt in Q1 2024 was driven primarily by the reclassification of debt obligations as they neared their maturity dates, along with the repayment or refinancing of certain portions of long-term debt.** This strategic reclassification led to a significant shift in the reported figures during the first quarter of 2024.  **[0001628280-24-020011_abt-20240331.htm:21]** **[0001628280-24-005348_abt-20231231.htm:66]** 

What drove the surge in the current portion of long-term debt in Q1 2024?

The significant increase in the current portion of long-term debt in Q3 2024 is primarily attributed to the modification of Abbott's yen-denominated 5-year term loan, which increased its principal from **£59.8 billion** to **£92.0 billion** and extended the maturity date to June 2029. Additionally, the net proceeds of approximately **$201 million** from this modification and the reclassification of debt maturing within the next 12 months into current liabilities further contributed to the increase.  **[0001628280-24-044602_abt-20240930.htm:2]** **[0001628280-24-044602_abt-20240930.htm:28]** 

Why did the current portion of long-term debt increase significantly in Q3 2024?

The **short-term investments** for the company decreased from **$383 million as of December 31, 2023** to **$232 million as of June 30, 2024**. Although the documents do not provide specific reasons for this decline, such changes are typically attributed to **shifts in investment strategies**, **reallocation of funds to other asset classes**, or **the use of funds for operational or strategic purposes**.  **[0001628280-24-033740_abt-20240630.htm:2]** 

What factors contributed to the decline in short-term investments in Q2 2024?

708d65ebee3a348210040dbf3416c5df331c195209a3fbd9eb3018dd0ca56e17

Cash and cash equivalents (USD, millions)

Trade receivables, less allowances (USD, millions)

Total inventories (USD, millions)

Net property and equipment (USD, millions)

Intangible assets, net of amortization (USD, millions)

Goodwill (USD, millions)

Trade accounts payable (USD, millions)

Current portion of long-term debt (USD, millions)

Long-term debt (USD, millions)

Post-employment obligations, deferred income taxes and other long-term liabilities (USD, millions)

Common shares (USD, millions)

Earnings employed in the business (USD, millions)

e1c88ecd6de2feda09176c69a36605e4190689443d8e069eb280b95cf5117cbc

426678ea8c5bb32c543e7975f6b6fe0ba72df506f29860d44180b086afdff522

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from / Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

f4428a02f5bc61e46e8e48f7bac86775adbd818acb98c9352a775221c6551049

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

76c3e3b51a719bc836808503ce252c25bcbe59379358d3a96ce9792e9c16fe83

0cd5c88bedb8d07d162097f5778c8938ae8dd31060363ba3083cf2f31d9607bd

513f2bfd6b03868d35f3ca867a3dde709c20d21d74babd987f5bd907fa1db545

United States

- Germany

- China

- India

- Switzerland

- Japan

- Netherlands

- All Other Countries

International

Total Revenue

2fe39869331038f519832b6474af95cd291fa3e93c1eae8bde53e89a0659efe8

ABBOTT LABORATORIES (ABT)

Financials